Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Rb plays a role in survival of Abl-dependent human tumor cells as a downstream effector of Abl tyrosine kinase

Oncogene volume 25, pages 493–502 (2006)Cite this article

Abstract

The retinoblastoma (Rb) gene product is a tumor suppressor that is mutated or inactivated in many types of human cancers. Although Rb is known to be an upstream negative regulator of Abl protein tyrosine kinase, we propose here that Rb also functions as a downstream effector of Abl that plays a positive role in survival of Abl-dependent human tumor cells, including Bcr/Abl-positive chronic myelogenous leukemia (CML). We show that Rb is constitutively phosphorylated at tyrosine in Abl-dependent tumor cells, and that Abl phosphorylates Rb specifically at Y805 within the C-terminal domain of the molecule. We also show that ectopic expression of Rb induces apoptosis in Abl-dependent tumor cells by inhibiting the Abl tyrosine kinase activity, and that Rb-induced apoptosis is compromised by Abl-catalysed phosphorylation of Rb at Y805. Furthermore, the silencing of endogenous Rb by RNA interference induced apoptosis in Abl-dependent tumor cells. Thus, our findings suggest that Abl-catalysed tyrosine phosphorylation of Rb is necessary for survival of Abl-dependent human tumor cells, and raises the possibility that this phosphorylated Rb can be a molecular target for cancer therapy aimed at inducing apoptosis of Abl-dependent tumor cells, such as Bcr/Abl-positive CML.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  • Baltimore D, Ren R, Cheng G, Alexandropoulos K, Cicchetti P . (1995). Ann NY Acad Sci 758: 339–344.

  • Baskaran R, Wood LD, Whitaker LL, Canman CE, Morgan SE, Xu Y et al. (1997). Nature 387: 516–519.

  • Bowen C, Birrer M, Gelmann EP . (2002). J Biol Chem 277: 44969–44979.

  • Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T . (1998). Nature 391: 597–601.

  • Calabretta B, Perrotti D . (2004). Blood 103: 4010–4022.

  • Chan HM, Krstic-Demonacos M, Smith L, Demonacos C, La Thangue NB . (2001). Nat Cell Biol 3: 667–674.

  • Chau BN, Borges HL, Chen TT, Masselli A, Hunton IC, Wang JY . (2002). Nat Cell Biol 4: 757–765.

  • Cujec TP, Medeiros PF, Hammond P, Rise C, Kreider BL . (2002). Chem Biol 9: 253–264.

  • Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. (2001). N Engl J Med 344: 1031–1037.

  • Guo XY, Balague C, Wang T, Randhawa G, Yuan Z, Bachier C et al. (1999). Oncogene 18: 1589–1595.

  • Harata M, Soda Y, Tani K, Ooi J, Takizawa T, Chen M et al. (2004). Blood 104: 1442–1449.

  • Harbour JW, Dean DC . (2000). Nat Cell Biol 2: E65–E67.

  • Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC . (1999). Cell 98: 859–869.

  • Helin K, Harlow E, Fattaey A . (1993). Mol Cell Biol 13: 6501–6508.

  • Horowitz JM, Yandell DW, Park SH, Canning S, Whyte P, Buchkovich K et al. (1989). Science 243: 937–940.

  • Janicke RU, Walker PA, Lin XY, Porter AG . (1996). EMBO J 15: 6969–6978.

  • Knudsen ES, Wang JY . (1997). Mol Cell Biol 17: 5771–5783.

  • Lewis JM, Baskaran R, Taagepera S, Schwartz MA, Wang JY . (1996). Proc Natl Acad Sci USA 93: 15174–15179.

  • Luo RX, Postigo AA, Dean DC . (1998). Cell 92: 463–473.

  • Ma D, Zhou P, Harbour JW . (2003). J Biol Chem 278: 19358–19366.

  • Magnaghi-Jaulin L, Groisman R, Naguibneva I, Robin P, Lorain S, Le Villain JP et al. (1998). Nature 391: 601–605.

  • Nevins JR . (1992). Science 258: 424–429.

  • Nguyen DX, Baglia LA, Huang SM, Baker CM, McCance DJ . (2004). EMBO J 23: 1609–1618.

  • Onadim Z, Hogg A, Baird PN, Cowell JK . (1992). Proc Natl Acad Sci USA 89: 6177–6181.

  • Sellers WR, Rodgers JW, Kaelin Jr WG . (1995). Proc Natl Acad Sci USA 92: 11544–11548.

  • Shafman T, Khanna KK, Kedar P, Spring K, Kozlov S, Yen T et al. (1997). Nature 387: 520–523.

  • Sherr CJ . (1996). Science 274: 1672–1677.

  • Shishido T, Akagi T, Ouchi T, Georgescu MM, Langdon WY, Hanafusa H . (2000). Proc Natl Acad Sci USA 97: 6439–6444.

  • Taagepera S, McDonald D, Loeb JE, Whitaker LL, McElroy AK, Wang JY et al. (1998). Proc Natl Acad Sci USA 95: 7457–7462.

  • Tan X, Wang JY . (1998). Trends Cell Biol 8: 116–120.

  • Taoka M, Ichimura T, Wakamiya-Tsuruta A, Kubota Y, Araki T, Obinata T et al. (2003). J Biol Chem 278: 5864–5870.

  • Wang JY . (2000). Oncogene 19: 5643–5650.

  • Weinberg RA . (1995). Cell 81: 323–330.

  • Wen ST, Jackson PK, Van Etten RA . (1996). EMBO J 15: 1583–1595.

  • Zhang J, Gray J, Wu L, Leone G, Rowan S, Cepko CL et al. (2004). Nat Genet 36: 351–360.

Download references

Acknowledgements

We thank Drs T Shishido and D Baltimore for providing Abl constructs, Novartis Pharmaceuticals Corporation for imatinib, and Ms N Okamura and S Hamada for the technical assistance. The Division of Proteomics Research is supported by Applied Biosystems, Japan and Millipore Corporation.

Author information

Authors and Affiliations

  1. Division of Proteomics Research, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo, Japan

    K Nagano, C Itagaki, T Izumi, K Nunomura & T Isobe

  2. Division of Molecular Therapy, Advanced Clinical Research Center, University of Tokyo, Minato-ku, Tokyo, Japan

    Y Soda

  3. Department of Advanced Molecular and Cell Therapy, Medical Institute of Bioregulation, Kyushu University, Maidashi, Higashi-ku, Fukuoka, Japan

    K Tani

  4. Department of Applied Biological Science, Tokyo University of Agriculture and Technology, Saiwai-cho, Tokyo, Fuchu-shi, Japan

    N Takahashi

  5. Division of Biochemistry, Institute of Medical Science, University of Tokyo, Shirokanedai, Minato-ku, Tokyo, Japan

    T Takenawa

Authors
  1. K Nagano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Itagaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Izumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Nunomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Y Soda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K Tani
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T Takenawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. T Isobe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T Isobe.

Additional information

Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nagano, K., Itagaki, C., Izumi, T. et al. Rb plays a role in survival of Abl-dependent human tumor cells as a downstream effector of Abl tyrosine kinase. Oncogene 25, 493–502 (2006). https://doi.org/10.1038/sj.onc.1208996

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208996

Keywords

This article is cited by

Search

Advanced search

Quick links